UPDATE: Berenberg Starts Athira Pharma (ATHA) at Buy

April 21, 2022 6:00 AM EDT
Get Alerts ATHA Hot Sheet
Price: $3.01 --0%

Rating Summary:
    2 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 6 | Down: 5 | New: 14
Join SI Premium – FREE
(Updated - April 21, 2022 6:00 AM EDT)

Berenberg analyst Esther Hong initiates coverage on Athira Pharma (NASDAQ: ATHA) with a Buy rating and a price target of $33.00.

The analyst comments "Pioneering a new frontier in Alzheimer’s disease: Athira Pharma, Inc (ATHA) is a clinical-stage biotech company focused on developing novel small molecules to restore neuronal health by inducing repair and regeneration of the brain and nerves. We view ATHA’s approach to treating Alzheimer’s disease as differentiated, with the potential to expand to other forms of dementia, which we believe the market is missing. In the near term, we look towards Phase 2 data this quarter to kick off the first of two key data readouts for lead drug fosgonimeton in Alzheimer’s disease. We initiate coverage of ATHA with a Buy rating and price target of USD33, implying 184% upside."

For an analyst ratings summary and ratings history on Athira Pharma click here. For more ratings news on Athira Pharma click here.

Shares of Athira Pharma closed at $11.63 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage